表紙
市場調査レポート

卵巣癌の薬物療法の企業・R&D・収益予測 (2015-2025年):近年の承認薬の高い市場潜在力

Ovarian Cancer Drug Therapy - Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential

発行 Visiongain Ltd 商品コード 336466
出版日 ページ情報 英文 180 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.81円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
卵巣癌の薬物療法の企業・R&D・収益予測 (2015-2025年):近年の承認薬の高い市場潜在力 Ovarian Cancer Drug Therapy - Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential
出版日: 2015年07月29日 ページ情報: 英文 180 Pages
概要

世界の卵巣癌治療薬の市場は2019年には17億1000万ドルの規模に成長すると予測されており、2025年にかけて大幅な収益成長を記録する見込みです。

当レポートでは、世界の卵巣癌の薬物療法の市場について調査し、卵巣癌および卵巣癌の診断・治療の種類と概要、主な卵巣癌治療薬、市場全体の主要動向および収益成長の見通し、薬剤クラス・地域/主要国別の動向と収益の推移と予測、主要企業のプロファイル・製品・取り組み、開発パイプランの動向、専門家へのインタビュー、SWOT分析などをまとめています。

第1章 レポート概要

第2章 イントロダクション:卵巣癌治療

  • 卵巣癌とは
    • 卵巣癌の症状
    • 卵巣癌のリスク因子
    • 卵巣癌の世界の発症率・有病率
  • 卵巣癌の診断
    • ラボテスト:CA125検査の不確定性
    • 初期卵巣癌に対するリゾホスファチジン酸アッセイの可能性
    • 卵巣癌診断の画像研究
  • 治療の選択肢
    • 化学療法
    • 標的療法
    • 免疫療法:最速成長の部門
      • モノクローナル抗体 (mAb)
      • 癌ワクチン
      • 非特異的免疫療法
    • ホルモン治療
    • 第一選択 (ファーストライン) 治療:プラチナ-タキサン療法
    • 第二選択 (セカンドライン) 治療
    • 第三選択 (サードライン) 治療

第3章 卵巣癌:世界市場の予測

  • 市場の現状
  • 市場予測
  • 市場成長推進因子・阻害因子
  • 部門別の市場シェア
  • 世界市場の展望:薬剤クラス別

第4章 主な卵巣癌治療薬

  • Avastin (Roche/中外製薬) - 世界市場のリーダー
    • 収益の推移
    • 予測
  • Lynparza (AstraZeneca)
    • 予測
  • Yondelis (Zeltia/Johnson & Johnson)
    • 収益の推移
    • 予測
  • その他

第5章 主要地域・国市場の予測

  • 地域別シェア
  • 米国:推移と予測
  • EU5カ国:推移と予測
    • ドイツ
    • フランス
    • 英国
    • スペイン
    • イタリア
  • 日本:推移と予測
  • 中国:推移と予測
  • インド:推移と予測
  • ブラジル:推移と予測
  • ロシア:推移と予測

第6章 主要企業

  • Johnson & Johnson (J&J)
  • Roche
  • AstraZeneca

第7章 卵巣癌治療薬の開発パイプラン

  • 第三相候補薬
    • Niraparib (TESARO)
    • Trebananib (Amgen/武田薬品工業)
    • Nintedanib (Boehringer Ingelheim)
    • Recentin (AstraZeneca)
    • Rucaparib (Clovis Oncology)
    • Opaxio (CTI BioPharma)
    • Binimetinib (Array Biopharma)
    • Lurbinectedin (PharmaMar)
    • Virgil (Gradalis)
    • Farletuzumab (エーザイ)
  • 第二相候補薬
    • CVac (Prima BioMed)
    • SG2000 (Spirogen)
    • Zoptarelin Doxorubicin (Aeterna Zentaris)
    • Reolysin (Oncolytics Biotech)
    • SGI110 (Astex Pharmaceuticals)
    • OvaRex (Quest PharmaTech)
    • Polyvalent Antigen-KLH複合ワクチン (MabVax Therapeutics)
    • Motolimod (VentiRx Pharmaceuticals)
    • Cyramza (Eli Lilly)
    • EGEN-001 (Celsion Corporation)
    • Ganetespib・Elesclomol (Synta Pharmaceuticals)
    • ENMD-2076 (CASI Pharmaceuticals)
    • GALE-301 (Galena Biopharma)
    • Epacadostat (Incyte Corporation)
    • AZD1775 (AstraZeneca)
    • Etirinotecan Pegol (Nektar Therapeutics)
    • Linsitinib (Astellas Pharmaceuticals)
    • Afuresertib (GlaxoSmithKline)
    • Zybrestat (OXiGENE)
    • Yervoy (Bristol-Myers Squibb)
    • Alisertib (武田薬品工業)
    • Voxtalisib with Pimasertib (Sanofi・Merck Serono)
    • Eli Lillyの第二相パイプラン:LY2606368・Olaratumab・Ralimetinib
    • MK2206 (Merck & Co.)
    • A6 Peptide (Angstrom Pharma)
    • Lifastuzumab Vedotin (Roche)
  • 第二相候補薬
    • VBL-111 (VBL Therapeutics)
    • MEDI4736 (AstraZeneca)
    • OVax (AVAX Technologies)
    • ME-344 (Novogen)
    • DPX-Survivac・DPX-0907 (Immunovaccine)

第8章 定性分析

  • SWOT分析
  • 市場機会と脅威
  • 法規制・価格決定上の制約
  • STEP分析
  • ポーターのファイブフォース分析

第9章 調査インタビュー

  • Dror Harats氏 (Prof., CEO, VBL Therapeutics)
  • Stuart Roberts氏 (Global Head of Investor Relations, Prima BioMed)
  • OXiGENE

第10章 総論

  • 世界市場の現状
  • 産業動向
  • 総論

図表

目次
Product Code: PHA0059

Ovarian Cancer Therapies - Explore Potentials of New Drugs, Industry Changes and Emerging Opportunities

What's the future for treating cancer of the human ovaries? Visiongain's new study forecasts those pharmaceutical revenues. There you find outlooks for sales growth in that industry. You also explore trends, results, treatments, R&D, and opportunities, seeing prospects.

Our report gives revenue predictions to 2025 at overall world market, submarket, product and national level. So avoid falling behind in data or losing influence. Instead discover, from 2015, what progress, opportunities and results are possible for those cancer treatments.

Read on, then, to explore ovarian cancer therapy and see what future revenues that pharma market could generate.

Forecasts and other analysis to benefit your research, assessments, plans and decisions

With our new study you explore prospects for companies developing, producing and marketing drugs for treating cancer of the ovaries. See present trends and future possibilities.

Besides revenue forecasting to 2025, our new work shows recent results, sales growth rates and market shares. There you find original analysis. Assess research and development too, seeing prospects. Also get 57 tables, 57 charts and three interviews with companies.

So avoid missing out on original data and discussions to help your work.

Treating ovarian tumours - find R&D and sales growth opportunities, helping your work

Our study's purpose is to help your research, analyses and decisions on those therapies, also benefiting your authority and reputation for insight.

The future holds high promise for organisations treating that gynaecological disorder. Discover the progress and gains possible there, avoiding struggles to find business information you need. See how patients, healthcare providers and companies can benefit.

Visiongain's analysis finds the ovarian cancer treatments market evolves, as new drugs enter the market and promising R&D pipeline candidates reach late-stage clinical trials. Discover what revenues are possible from 2015 in that expanding pharma segment.

Opportunities for pharmaceutical companies open there, giving high sales potentials. Our new study finds that market can achieve strong revenue growth from 2015 to 2025, driven by expanding patient populations and revenues from recent and expected product launches.

Though no such study covers everything, the following sections show how our new investigation benefits your work.

Forecasting that world market and sub-segments for treating ovarian cancer

What are the secrets of that technology's progress? And what potential does it have? Find in our report overall world revenue to 2025 for those antineoplastic medicines - existing, emerging and expected drugs.

Also explore individual revenue predictions to 2025 for four therapeutic submarkets at world level:

  • Chemotherapy
  • Targeted therapies
  • Immunotherapy
  • Hormonal treatments.

Where lie the best sales potentials? With our analysis you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors' actions and prospects.

See how those cancer-treating medicines develop, hearing where needs and business opportunities exist. With a growing incidence of ovarian cancer and high recurrence and mortality rates, the demand for better treatments will continue to bolster that drug market.

You also find sales predictions by product, exploring how they can succeed.

Predictions of leading products' sales - what's possible for those cancer-treating drugs?

How will individual medicines perform from 2015 to 2025 at world level? Our study forecasts ovarian cancer treatment revenues of these three brands:

  • Avastin (bevacizumab)
  • Lynparza (olaparib).
  • Yondelis (trabectedin).

There you discover how high sales can go, finding medicines and years with highest predicted revenues. Also examine competition. That way you investigate what's happening, understanding challenges, trends, competitors and opportunities.

Discover what the future holds. Our work also shows you geographical predictions, by country.

Healthcare in national markets - what outlooks for ovarian cancer drug revenues?

Advances in the biopharma industry and market expand the use of drugs to treat ovarian cancer. Discover those technologies' international sales prospects.

Our work shows you individual revenue forecasts to 2025 for 11 national markets:

  • United States (US)
  • Japan
  • Germany, France, the United Kingdom (UK), Italy and Spain (EU5 group)
  • Brazil, Russia, India and China (BRIC countries).

You assess countries with highest revenues and potential growth. Explore outlooks for treating that disease, including patients' and healthcare providers' needs. That way you find opportunity in treating ovarian tumours. See what the future holds for companies.

You also examine developments leading to novel treatments.

R&D for those cancer therapies - developmental trends, innovations and progress

In our study you investigate that oncology - research and development on ovarian tumours. You examine these advances and others, seeing clinical progress and what it means:

  • PARP inhibition
  • Biologically enhanced chemotherapeutics
  • Tumour vascular disruption
  • Angiokinase inhibition
  • Cytotoxic technology based on pyrrolobenzodiazepine
  • Luteinising hormone-releasing hormone (LHRH) therapy
  • Polyvalent antigen-KLH conjugate vaccine
  • IL-12 immunotherapy
  • Kinase inhibitors and anti-angiogenic treatment.

Explore other issues too, including these forces shaping that industry and market:

  • Monoclonal antibodies (mAbs), cancer vaccines and antibody-drug conjugates
  • Prevalence and incidence of ovarian cancer - expanding patient populations
  • Competition from generic drugs and pressure from governmental price regulation
  • Alliances, mergers and acquisitions (M&A) - changes in the industry.

Our study shows progress in preventing, inhibiting and halting those neoplasms. You also gain SWOT, STEP and Porter's five forces analyses.

Ovarian cancer R&D holds strength, variety and promise. See, then, what's possible for big pharma companies and specialists in biological drugs and related biotechnologies.

Companies and overall 2019 market value - what revenues possible?

Our work predicts the world market for ovarian cancer-treating drugs will reach $1.71bn in 2019. That industry will achieve strong revenue expansion from 2015 to 2025. With our analysis you find how high sales can go, seeing what is possible for those drug producers.

You also discover what companies hold most potential. For those therapies, explore pharmaceutical developers, producers and marketers, including these firms:

  • Roche
  • AstraZeneca
  • Johnson & Johnson
  • Zeltia
  • Chugai.

You find 127 organisations mentioned. Also see interviews with Prima BioMed, OXiGENE and VBL Therapeutics. Discover what the future holds for companies treating those disorders of the ovary.

Ways Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025 helps you

Our new investigation benefits your work in these seven main ways, helping you stay ahead:

  • Revenues for ovarian cancer treatments to 2025 - assess that overall world market's potential, seeing scope for investments, developments and marketing
  • Submarket revenues to 2025 for chemotherapy, targeted therapies, immunotherapy and hormonal drugs - explore segments, seeing their sales outlooks
  • Products' sales to 2025 - discover predicted revenues of Avastin, Lynparza and Yondelis, seeing how those medicines can compete and succeed
  • National market forecasting to 2025 for 11 countries in the Americas, Europe and Asia - explore the best regions for treatment demand, sales and growth
  • R&D activities - see progress, trends and prospects in that oncological research and development, finding technological, clinical and commercial possibilities
  • Companies, news and opinions - examine participants in that rising market, and gain three interviews, helping your reputation for insight and staying ahead
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths there, helping you compete and gain advantages.

That survey, by our in-house UK-based analysts, gives knowledge to benefit your research, analyses, plans, decisions and proposals. It shows information you find nowhere else.

Discover predictions for treating ovarian cancer, getting information to help you now

With our independent analyses you explore products, companies, progress and possibilities. Discover the best commercial opportunities, as well as ways to help patients.

Having that data means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how you could save time and effort, also benefiting your plans, decisions, presentations, proposals and authority.

Try that study. Our investigation shows data, trends, opportunities and sales forecasts for that strong, expanding drugs market. So avoid missing out - please get our new report here now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of the World Market for Ovarian Cancer Treatment
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Main Questions Answered by This Analysis
  • 1.5. Who Is This Study For?
  • 1.6. Methods of Research and Analysis
  • 1.7. Frequently Asked Questions (FAQs)
  • 1.8. Some Associated Reports
  • 1.9. About Visiongain
  • 1.10. Abbreviations Frequently Used in This Report

2. An Introduction to Ovarian Cancer Therapy

  • 2.1. Overview of Ovarian Cancer
    • 2.1.1. Symptoms of Ovarian Cancer
    • 2.1.2. Risk Factors for Ovarian Cancer
    • 2.1.3. Global Prevalence and Incidence of Ovarian Cancer
  • 2.2. Diagnosing Ovarian Cancer
    • 2.2.1. Laboratory Testing: The Uncertainty of CA 125 Testing
    • 2.2.2. The Potential of Lysophosphatidic Acid Assay for Early Stage Ovarian Cancer
    • 2.2.3. Imaging Studies for Diagnosing Ovarian Cancer
  • 2.3. Treatment Options for Cancer
    • 2.3.1. Chemotherapy
    • 2.3.2. Targeted Therapy
    • 2.3.3. Immunotherapy: Fastest Growing Sector in Cancer Therapy
      • 2.3.3.1. Monoclonal Antibodies (mAbs)
      • 2.3.3.2. Cancer Vaccines
      • 2.3.3.3. Non-Specific Immunotherapies
    • 2.3.4. Hormone Therapy
    • 2.3.5. First-Line Therapy: Platinum-Taxane Treatment
    • 2.3.6. Second-Line Therapy
    • 2.3.7. Maintenance Therapy

3. Ovarian Cancer: World Market 2015-2025

  • 3.1. Ovarian Cancer Therapies Market, 2014
    • 3.1.1. A Note on Monoclonal Antibodies in this Report
  • 3.2. Ovarian Cancer Therapies Market Forecast, 2015-2025
  • 3.3. Driving and Restraining Forces Affecting the Ovarian Cancer Therapy Market
    • 3.3.1. Increasing Patient Population
    • 3.3.2. Intense Competition from Generics
  • 3.4. The Ovarian Cancer Therapy Submarket Shares, 2019 and 2025
  • 3.5. The Future of the World Market for Ovarian Cancer Therapy by Therapeutic Class: Grouped Revenue Forecasts, 2014-2025
    • 3.5.1. Targeted Therapy-Leading Submarket in Ovarian Cancer Therapy by 2025
    • 3.5.2. Chemotherapy-Remains First-Line Treatment for Ovarian Cancer
    • 3.5.3. Immunotherapy-The Fastest Growing Segment in Cancer Therapy
    • 3.5.4. Hormone Therapy-Rare Treatment in Ovarian Cancer

4. Leading Ovarian Cancer Drugs 2014

  • 4.1. Avastin (Roche/Chugai) - The World Market Leader
    • 4.1.1. Avastin Revenue, 2010-2014 - Mixed Growth
    • 4.1.2. Avastin Ovarian Cancer Forecast, 2015-2025
  • 4.2. Lynparza (AstraZeneca)
    • 4.2.1. Lynparza Forecast 2015-2025
  • 4.3. Yondelis (Zeltia/Johnson & Johnson)
    • 4.3.1. Yondelis (Zeltia/Johnson & Johnson): Historical Revenues
    • 4.3.2. Yondelis Forecast 2015-2025
  • 4.4. Other Ovarian Cancer Therapies

5. Leading Regional and National Markets in the Ovarian Cancer Therapy 2015-2025

  • 5.1. Regional Breakdown of the World Ovarian Cancer Therapeutics Market
    • 5.1.1. How Will Regional Market Shares Change to 2025?
  • 5.2. The US Ovarian Cancer Drug Therapy Market, 2014
    • 5.2.1. US Ovarian Cancer Therapeutics Market Forecast, 2015-2025
  • 5.3. The Ovarian Cancer Therapy Market in the EU5 Markets to 2025
    • 5.3.1. German Ovarian Cancer Therapy Market Forecast, 2015-2025
    • 5.3.2. French Ovarian Cancer Therapy Market Forecast, 2015-2025
    • 5.3.3. UK: Pharmaceutical Price Regulation Scheme and Market Forecast, 2015-2025
      • 5.3.3.1. NICE: Guidance for Ovarian Cancer Therapies
    • 5.3.4. Spanish Ovarian Cancer Therapy Market Forecast, 2015-2025
    • 5.3.5. Italian Ovarian Cancer Therapy Market Forecast, 2015-2025
  • 5.4. Japan: Growth in Generics - Ovarian Cancer Therapy Market Forecast, 2015-2025
  • 5.5. Chinese Ovarian Cancer Therapy Market Forecast, 2015-2025
  • 5.6. Indian Ovarian Cancer Therapy Market Forecast, 2015-2025
  • 5.7. Brazilian Ovarian Cancer Therapy Market Forecast, 2015-2025
  • 5.8. Russian Ovarian Cancer Therapy Market Forecast, 2015-2025

6. Leading Companies in the Ovarian Cancer Therapy Market

  • 6.1. Companies with Exclusivity in 2014
  • 6.2. Johnson & Johnson (J&J)
    • 6.2.1. Sales and Performance Analysis, 2014
    • 6.2.2. Pharmaceutical Segment Sales Analysis, 2014
      • 6.2.2.1. R&D Performance Analysis, 2014
    • 6.2.3. Recent M&A Activity: J&J Acquires Alios BioPharma and Aragon Pharmaceuticals
  • 6.3. Roche
    • 6.3.1. Sales and Performance Analysis, 2014
    • 6.3.2. Pharmaceutical Segment Sales Analysis, 2014
      • 6.3.2.1. Cancer Drug Sales and Performance Analysis, 2014
      • 6.3.2.2. Pharmaceutical Segment R&D Performance Analysis, 2014
    • 6.3.3. Recent M&A Activity
  • 6.4. AstraZeneca
    • 6.4.1. Sales and Performance Analysis, 2014
    • 6.4.2. Pharmaceutical Segment Sales Analysis, 2014
      • 6.4.2.1. Cancer Drug Sales and Performance Analysis, 2014
      • 6.4.2.2. R&D Performance Analysis, 2014
    • 6.4.3. Recent M&A Activity: The Pfizer and AstraZeneca Saga

7. Ovarian Cancer Therapy: Developmental Pipelines 2015

  • 7.1. Ovarian Cancer Phase III Candidates 2015
    • 7.1.1. Niraparib (TESARO): Leading the PARP Inhibitors in the Pipeline
      • 7.1.1.1. TESARO and Merck to Collaborate: Niraparib and Keytruda
    • 7.1.2. Trebananib (Amgen/Takeda Pharmaceuticals): Misses Key Survival Measure in Phase III
    • 7.1.3. Nintedanib (Boehringer Ingelheim): Triple Angiokinase Inhibitor
    • 7.1.4. Recentin (AstraZeneca): Promising Results in Phase III
    • 7.1.5. Rucaparib (Clovis Oncology): ARIEL2 and ARIEL3
    • 7.1.6. Opaxio (CTI BioPharma): Biologically Enhanced Chemotherapeutic
    • 7.1.7. Binimetinib (Array Biopharma): Expected Filing in 2016
    • 7.1.8. Lurbinectedin (PharmaMar): Second-Generation Analogue of Yondelis (Trabectedin)
    • 7.1.9. Virgil (Gradalis): Autologous Tumour Cell Vaccine
    • 7.1.10. Farletuzumab (Eisai): Failure in Phase III
  • 7.2. Ovarian Cancer Phase II Candidates 2015
    • 7.2.1. CVac (Prima BioMed): MUC-1 Cancer Vaccine
    • 7.2.2. SG2000 (Spirogen): Cytotoxic Technology Based on Pyrrolobenzodiazepines
    • 7.2.3. Zoptarelin Doxorubicin (Aeterna Zentaris): Luteinising Hormone-Releasing Hormone (LHRH)
    • 7.2.4. Reolysin (Oncolytics Biotech)
    • 7.2.5. SGI110 (Astex Pharmaceuticals)
    • 7.2.6. OvaRex (Quest PharmaTech)
    • 7.2.7. Polyvalent Antigen-KLH Conjugate Vaccine (MabVax Therapeutics)
    • 7.2.8. Motolimod (VentiRx Pharmaceuticals): Toll-Like Receptor 8 Agonist
    • 7.2.9. Cyramza (Eli Lilly): Expanding Approved Indications
    • 7.2.10. EGEN-001 (Celsion Corporation): IL-12 Immunotherapy
    • 7.2.11. Ganetespib and Elesclomol (Synta Pharmaceuticals)
    • 7.2.12. ENMD-2076 (CASI Pharmaceuticals)
    • 7.2.13. GALE-301 (Galena Biopharma): Folate Binding Protein Vaccine
    • 7.2.14. Epacadostat (Incyte Corporation): IDO1 Inhibitor
    • 7.2.15. AZD1775 (AstraZeneca): WEE1 Kinase Inhibitor
    • 7.2.16. Etirinotecan Pegol (Nektar Therapeutics): Promising Phase II Results
    • 7.2.17. Linsitinib (Astellas Pharmaceuticals): Development Discontinued?
    • 7.2.18. Afuresertib (GlaxoSmithKline): Multiple Oncology Indications
    • 7.2.19. Zybrestat (OXiGENE): Vascular Disrupting Agent
    • 7.2.20. Yervoy (Bristol-Myers Squibb)
    • 7.2.21. Alisertib (Takeda Pharmaceuticals): Aurora A Kinase Inhibitor
    • 7.2.22. Voxtalisib with Pimasertib (Sanofi and Merck Serono)
    • 7.2.23. Eli Lilly's Phase II Ovarian Cancer Pipeline: LY2606368, Olaratumab & Ralimetinib
    • 7.2.24. MK2206 (Merck & Co.): AKT Inhibitor
    • 7.2.25. A6 Peptide (Angstrom Pharma)
    • 7.2.26. Lifastuzumab Vedotin (Roche): Antibody Drug Conjugate
  • 7.3. Ovarian Cancer Phase II Candidates 2015
    • 7.3.1. VBL-111 (VBL Therapeutics): Anti-Angiogenic Agent
    • 7.3.2. MEDI4736 (AstraZeneca)
    • 7.3.3. OVax (AVAX Technologies)
    • 7.3.4. ME-344 (Novogen)
    • 7.3.5. DPX-Survivac and DPX-0907 (Immunovaccine): Two Novel Immunotherapies

8. Qualitative Analysis of the Ovarian Cancer Therapy Market 2015-2025

  • 8.1. SWOT Analysis of the Ovarian Cancer Therapeutics Market
    • 8.1.1. Strengths and Weaknesses of the Market
    • 8.1.2. The Rising Incidence of Cancer
    • 8.1.3. Drug Development Challenges
  • 8.2. Opportunities and Threats for the Market
    • 8.2.1. Advances in Research Open the Doors for Personalised Therapy
  • 8.3. Regulations and Pricing Restrictions
  • 8.4. STEP Analysis of the Ovarian Cancer Therapy Market
    • 8.4.1. Social Factors: An Expanding Patient Population and Increasing Awareness
    • 8.4.2. Technological Advances: DNA Sequencing of High-Grade Serous Ovarian Carcinoma
    • 8.4.3. Economic Factors: Cost Cutting in the EU and the US
    • 8.4.4. Political Factors: Will the Affordable Care Act Increase Patient Access to Anti-Cancer Drugs?
  • 8.5. Porter's Five Forces Analysis of the Ovarian Cancer Therapeutics Market
    • 8.5.1. Rivalry Among Competitors
    • 8.5.2. Threat of New Entrants
    • 8.5.3. Power of Suppliers
    • 8.5.4. Power of Buyers
    • 8.5.5. Threat of Substitutes

9. Research Interviews

  • 9.1. Interview with Prof. Dror Harats, CEO, VBL Therapeutics
    • 9.1.1. Outlook for VB-111 in the Ovarian Cancer Market
    • 9.1.2. Drivers and Restraints in the Ovarian Cancer Market
    • 9.1.3. Trends in the Ovarian Cancer Market
    • 9.1.4. Outlook for VBL Therapeutics in the Oncology Market
  • 9.2. Interview with Mr Stuart Roberts, Global Head of Investor Relations, Prima BioMed
    • 9.2.1. Outlook for CVac in the Ovarian Cancer Market
    • 9.2.2. The Ovarian Cancer Market
    • 9.2.3. Trends in the Ovarian Cancer Market
    • 9.2.4. Outlook for Prima BioMed in the Oncology Market
  • 9.3. Interview with a Representative of OXiGENE
    • 9.3.1. Outlook for Zybrestat in the Ovarian Cancer Market
    • 9.3.2. The Ovarian Cancer Market in 2015
    • 9.3.3. Trends in the Ovarian Cancer Market, 2015-2025
    • 9.3.4. Outlook for OXiGENE in the Oncology Market

10. Conclusions from the Research and Analysis

  • 10.1. The World Ovarian Cancer Therapeutics Market in 2014
    • 10.1.1. Leading National Markets to 2025
  • 10.2. Trends in the Industry
    • 10.2.1. Growing Interest in Personalised Therapy
    • 10.2.2. Multiple Late-Stage Pipeline Drugs
  • 10.3. Concluding Remarks

List of Tables

  • Table 1.1: Ovarian Cancer Therapy Market Forecast, 2014-2025
  • Table 1.2: Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2013 and 2014
  • Table 2.1: Types of Ovarian Cancer
  • Table 2.2: Stages of Ovarian Cancer
  • Table 2.3: Grades of Ovarian Cancer
  • Table 2.4: 5-Year Prevalence for Ovarian Cancer by Region, 2012
  • Table 2.5: Incidence Rates for Ovarian Cancer by Country, 2012
  • Table 2.6: Cancer-Treating Agents: Chemotherapy, Immunotherapy, Targeted Therapy and Hormone Therapy, 2015
  • Table 3.1: The World Ovarian Cancer Therapy Market by Therapeutic Class: Revenues ($bn) and Market Shares (%), 2014
  • Table 3.2: The World Ovarian Cancer Therapy Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 3.3: The World Ovarian Cancer Therapy Market by Therapeutic Class: Revenues ($bn) and Market Shares (%), 2019 and 2025
  • Table 3.4: The World Ovarian Cancer Therapy Market by Therapeutic Class: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 3.5: Global Ovarian Cancer Targeted Therapy Market: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 3.6: Global Ovarian Cancer Chemotherapy Market: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 3.7: Global Ovarian Cancer Immunotherapy Market: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 3.8: Global Ovarian Cancer Hormone Therapy Market: Revenues ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 4.1: Avastin Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
  • Table 4.2: Avastin Ovarian Cancer Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
  • Table 4.3: Lynparza Ovarian Cancer Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
  • Table 4.4: Yondelis Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
  • Table 4.5: Yondelis Ovarian Cancer Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
  • Table 5.1: Ovarian Cancer Therapy Market: Revenue ($bn) and Market Share (%) by Country, 2014
  • Table 5.2: Ovarian Cancer Drug Therapy Market: Revenue ($bn), AGR (%) and CAGR (%) by Country, 2015-2025
  • Table 5.3: Ovarian Cancer Therapy Revenue ($bn) and Market Share (%) by Country, 2014, 2019 and 2025
  • Table 5.4: US Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.5: EU5 Ovarian Cancer Drug Therapy Markets: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.6: German Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.7: French Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.8: UK Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.9: Spanish Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.10: Italian Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.11: apanese Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.12: Chinese Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.13: Indian Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.14: Brazilian Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.15: Ovarian Cancer Mortality Rate by Country, 2012
  • Table 5.16: Russian Ovarian Cancer Therapy Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 6.1: J&J Revenue ($bn) and Revenue Share (%) by Sector, 2014
  • Table 6.2: J&J Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
  • Table 6.3: J&J: Pharmaceutical Revenue ($bn) and Revenue Share (%) by Segment, 2013 and 2014
  • Table 6.4: J&J: R&D Expenses ($bn) and Share (%) of Company Revenue, 2012-2014
  • Table 6.5: Roche Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
  • Table 6.6: Roche: Pharmaceutical Revenue ($bn) and Revenue Share (%) by Therapeutic Area, 2013 and 2014
  • Table 6.7: Roche: Anti-cancer Drug Revenues ($bn) and CAGR (%) by Therapeutic Area, 2012-2014
  • Table 6.8: Roche: Pharmaceutical R&D Expenses as a Percentage (%) of Company Revenue, 2012-2014
  • Table 6.9: Roche: Phase II Oncology Pipeline, 2015
  • Table 6.10: Roche: Phase III Oncology Pipeline, 2015
  • Table 6.11: AstraZeneca Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
  • Table 6.12: AstraZeneca: Revenue ($bn) and Revenue Shares (%) by Therapeutic Area, 2013 and 2014
  • Table 6.13: AstraZeneca: Anti-cancer Drug Revenues ($bn) and CAGR (%), 2012-2014
  • Table 6.14: AstraZeneca: R&D Expenses ($bn) and Share (%) of Company Revenue, 2012-2014
  • Table 6.15: AstraZeneca: Ovarian Cancer R&D Pipeline, 2014
  • Table 7.1: Selected Late-Phase Pipeline Candidates for Ovarian Cancer, 2015
  • Table 7.2: Selected Phase II Pipeline Candidates for Ovarian Cancer, 2015
  • Table 7.3: Selected Phase II Pipeline Candidates for Ovarian Cancer, 2015 (Continued)
  • Table 7.4: Selected Early Phase Pipeline Candidates for Ovarian Cancer, 2015
  • Table 8.1: Strengths and Weaknesses of the Ovarian Cancer Therapy Market, 2015-2025
  • Table 8.2: Opportunities and Threats Facing the Ovarian Cancer Therapy Market, 2015-2025
  • Table 8.3: Social, Technological, Economic and Political Forces Influencing the Ovarian Cancer Therapy Market (STEP Analysis), 2015-2025

List of Figures

  • Figure 2.1: 5-Years Prevalence for Ovarian Cancer by Region, 2012
  • Figure 2.2: Incidence Rates for Ovarian Cancer by Country, 2012
  • Figure 3.1: the World Ovarian Cancer Therapy Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Figure 3.2: Ovarian Cancer Therapy Market: Drivers and Restraints, 2015-2025
  • Figure 3.3: Ovarian Cancer Therapy Market by Therapeutic Class, 2019
  • Figure 3.4: Ovarian Cancer Therapy Market by Therapeutic Class, 2025
  • Figure 3.5: The Global Ovarian Cancer Therapy Market by Therapeutic Class: Revenue Forecasts ($bn), 2015-2025
  • Figure 3.6: Global Ovarian Cancer Targeted Therapy Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.7: Ovarian Cancer Targeted Therapy Market: Drivers and Restraints, 2015-2025
  • Figure 3.8: Global Ovarian Cancer Chemotherapy Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.9: Ovarian Cancer Chemotherapy Market: Drivers and Restraints, 2015-2025
  • Figure 3.10: Global Ovarian Cancer Immunotherapy Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.11: Ovarian Cancer Immunotherapy Market: Drivers and Restraints, 2015-2025
  • Figure 3.12: Global Ovarian Cancer Hormone Therapy Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.13: Ovarian Cancer Hormone Therapy Market: Drivers and Restraints, 2015-2025
  • Figure 4.1: Avastin Revenue ($bn) and AGR (%), 2010-2014
  • Figure 4.2: Avastin Ovarian Cancer Revenue ($bn) Forecast, 2015-2025
  • Figure 4.3: Avastin: Drivers and Restraints, 2015-2025
  • Figure 4.4: Lynparza Ovarian Cancer Revenue ($bn) Forecast, 2015-2025
  • Figure 4.5: Lynparza: Drivers and Restraints, 2015-2025
  • Figure 4.6: Yondelis Revenue ($bn) and AGR (%), 2010-2014
  • Figure 4.7: Yondelis Ovarian Cancer Revenue ($bn) Forecast, 2015-2025
  • Figure 4.8: Yondelis: Drivers and Restraints, 2015-2025
  • Figure 5.1: Ovarian Cancer Drug Therapy Market Share (%) by Country, 2014
  • Figure 5.2: Developed National Markets: Drivers and Restraints, 2015-2025
  • Figure 5.3: Emerging National Markets: Drivers and Restraints, 2015-2025
  • Figure 5.4: Ovarian Cancer Therapy Market Share (%) by Country, 2019
  • Figure 5.5: Ovarian Cancer Therapy Market Share (%) by Country, 2025
  • Figure 5.6: US Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
  • Figure 5.7: EU5 Ovarian Cancer Therapy Markets: Revenue ($bn) Forecasts, 2015-2025
  • Figure 5.8: German Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
  • Figure 5.9: French Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
  • Figure 5.10: UK Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
  • Figure 5.11: Spanish Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
  • Figure 5.12: Italian Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
  • Figure 5.13: Japanese Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
  • Figure 5.14: Chinese Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
  • Figure 5.15: Indian Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
  • Figure 5.16: Brazilian Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
  • Figure 5.17: Ovarian Cancer Mortality Rate by Country, 2012
  • Figure 5.18: Russian Ovarian Cancer Therapy Market: Revenue ($bn) Forecast, 2015-2025
  • Figure 6.1: J&J Revenue Share (%) by Sector, 2014
  • Figure 6.2: J&J Historical Revenue ($bn) and AGR (%), 2010-2014
  • Figure 6.3: J&J: Revenue Share (%) by Segment, 2014
  • Figure 6.4: J&J: R&D Expenses ($bn) and Share (%) of Company Revenue, 2012-2014
  • Figure 6.5: Roche Historical Revenue ($bn) and AGR (%), 2010-2014
  • Figure 6.6: Roche: Pharmaceutical Revenue Share (%) by Segment, 2014
  • Figure 6.7: Roche: Anti-cancer Drug Revenue Share (%), 2014
  • Figure 6.8: Roche: Pharmaceutical R&D Expenses as a Percentage (%) of Company Revenue, 2012-2014
  • Figure 6.9: AstraZeneca Historical Revenue ($bn) and AGR (%), 2010-2014
  • Figure 6.10: AstraZeneca: Revenue ($bn) by Therapeutic Area, 2013 and 2014
  • Figure 6.11: AstraZeneca: Revenue Share (%) by Therapeutic Area, 2014
  • Figure 6.12: AstraZeneca: Anti-cancer Drugs Revenue Share (%) by Drug, 2014
  • Figure 6.13: AstraZeneca: R&D Expenses ($bn) and Share (%) of Company Revenue, 2012-2014
  • Figure 8.1: Porter's Five Forces Analysis of the Ovarian Cancer Drug Therapy Market, 2015-2025
  • Figure 10.1: Ovarian Cancer Therapy Market: Revenue Shares ($bn) by Drug, 2014-2025
  • Figure 10.2: Ovarian Cancer Therapy Market Revenue ($bn) by Country, 2014, 2019 and 2025

Companies Listed

  • AbbVie
  • Actavis
  • Advaxis
  • Aeterna Zentaris
  • Alios BioPharma (part of J&J)
  • Almirall
  • American Cancer Society
  • American Society of Clinical Oncology
  • Amgen
  • Angstrom Pharma
  • Array BipPharma
  • Astellas Pharma
  • Astex Pharmaceuticals
  • AstraZeneca
  • Australia and New Zealand Gynecological Oncology Group (ANZGOG)
  • Autorità Garante della Concorrenza e del Mercato (Italian Competition Authority)
  • Auven Therapeutics
  • AVAX Technologies
  • Baxter Healthcare
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Busto Arisizio Hospital [Italy]
  • Cancer Research Institute
  • Cancer Research UK
  • Cancer Treatment Centers of America
  • CASI Pharmaceuticals
  • Celgene
  • Cell Therapeutics
  • Celsion Corporation
  • Cerulean Pharma
  • Chiba University Hospital
  • Clovis Oncology
  • CTI BioPharma (formerly Cell Therapeutics)
  • Eisai
  • Eli Lilly
  • ENGOT
  • EntreMed (now CASI Pharmaceuticals)
  • European Commission (EC)
  • Expression Genetics
  • Facing Our Risk of Cancer Empowered (FORCE)
  • Food and Drug Administration [US]
  • Fox Chase Cancer Center
  • Fresenius Biotech North America
  • Galena Biopharma
  • GCIG
  • Genia (part of Roche)
  • Genentech
  • GlaxoSmithKline
  • Gradalis
  • Grupo Español de Investigación en Cáncer de Ovario (GEICO)
  • Gynecologic Oncology Group
  • Immunovaccine
  • Immutep
  • Incyte
  • Indiana University School of Medicine
  • InterMune (part of Roche)
  • International Agency for Research on Cancer (IARC)
  • International Gynecologic Cancer Society (IGCS)
  • Janssen Biotech (part of Janssen Pharmaceutical Companies)
  • Janssen Pharmaceutical (part of J&J)
  • Janssen Products (part of Janssen Pharmaceutical Companies)
  • Jiangsu Hengrui Med
  • Johnson & Johnson (J&J)
  • Jubilant Biosys
  • Ludwig Institute for Cancer Research
  • MabVax Therapeutics
  • Marshall Edwards (now MEI Pharma)
  • Massachusetts General Hospital
  • McGill University
  • Medical Research Council [UK]
  • Medical University Innsbruck
  • MedImmune (part of AstraZeneca)
  • MEI Pharma (part of Novogen)
  • Memorial Sloan-Kettering Cancer Center
  • Menarini Group
  • Merck & Co.
  • Morphotek, Inc. (part of Eisai)
  • Myriad Genetics
  • National Cancer Institute [US]
  • National Health and Medical Research Council [Australia]
  • National Health Service (NHS) [UK]
  • NCIC Clinical Trials Group
  • National Institute for Health and Care Excellence (NICE) [UK]
  • National Institutes of Health (NIH) [US]
  • National Institutes of Health Clinical Center (NIHCC) [US]
  • Nektar Therapeutics
  • Neopharm Group
  • Nordic Society for Oncology
  • Novartis
  • Novogen
  • NRG Oncology
  • OBI Pharma
  • Oncolytics Biotech
  • Onconova Therapeutics
  • Orion Genomics
  • OXiGENE
  • Peter MacCallum Cancer Centre
  • PharmaMar (part of Zeltia Group)
  • Poniard Pharmaceuticals
  • Prima BioMed
  • Quest PharmaTech
  • Roche
  • Roxane
  • Sandoz (part of Novartis)
  • Sanofi
  • Santaris (part of Roche)
  • SCRI Development Innovations
  • Seragon Pharmaceuticals (part of Roche)
  • Society of Gynecologic Oncology
  • Spirogen
  • Stanford University
  • Sunesis Pharmaceuticals
  • Surveillance, Epidemiology and End Results Program (SEER) [US]
  • Synta Pharmaceuticals
  • Taiho Pharmaceutical
  • Takeda Pharmaceuticals
  • TESARO
  • University College London
  • University of Queensland's Institute for Molecular Biosciences (IMB)
  • Vascular Biogenics Ltd (VBL Therapeutics)
  • VBL Therapeutics
  • VentiRx Pharmaceuticals
  • Westmead Millennium Institute for Medical Research
  • World Cancer Research Fund International
  • Worldwide Cancer Research
  • Zeltia Group
  • Zybrestat
Back to Top